MedTrace Logo

Assessing the Effectiveness and Feasibility of Voluntary Assisted Partner Notification Services

NCT03944395 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1785

Last updated 2019-08-13

No results posted yet for this study

Summary

To evaluate effectiveness of voluntary assisted partner notification (VAPN) in real-world programmatic settings, a non-randomized, stepped wedge study in high volume facilities in 6 high HIV burden focus districts (Blantyre, Zomba, Chikwawa, Machinga, Mangochi and Lilongwe urban) is proposed. The primary objective is to compare the percentage of contacts tested during the standard of care (SOC) phase (i.e., using passive family referral services (FRS) index testing methodology) with the percentage of contacts tested during the SOC plus VAPN phase, by 1, 2, and 3 months after the initial contact with the index client. Assessment of feasibility will be achieved through documentation of operational lessons learned during implementation. Findings will contribute to ongoing policy discussions whether Malawi should adopt VAPN in its national HIV testing guidelines

Conditions

  • HIV Infections

Interventions

OTHER

Assisted Partner Notification Services

Three options for partner Notification services; contract referral, provider referral and dual referral

Sponsors & Collaborators

  • United States Agency for International Development (USAID)

    collaborator FED

  • Centers for Disease Control and Prevention

    collaborator FED

  • Elizabeth Glaser Pediatric AIDS Foundation

    collaborator OTHER

  • Ministry of Health, Malawi

    collaborator OTHER_GOV

  • Lighthouse Trust

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-21
Primary Completion
2020-04-29
Completion
2020-04-29

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03944395 on ClinicalTrials.gov